Sjuts Dustin S 4
4 · Revance Therapeutics, Inc. · Filed Jan 3, 2023
Insider Transaction Report
Form 4
Sjuts Dustin S
Chief Commercial Officer
Transactions
- Award
Common Stock
2022-12-31$12.18/sh+605$7,369→ 95,812 total
Footnotes (1)
- [F1]These shares were acquired by Mr. Sjuts under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).